Respiratory system disorder
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Respiratory system disorder
- Therapeutic area
- Pulmonology
- respiratory system disorder
- disease of respiratory system
- disease or disorder of respiratory system
- disorder of respiratory system
- respiratory disease
- respiratory disorder
- respiratory system disease
- respiratory system disease or disorder
- All therapeutic areas
- Pulmonology
Sources for recorded values
- Severity
- Unknown
- MONDO ID
- MONDO:0005087
- Parent condition
- MONDO:7770006
Related records
Broader conditions (3)
- Disease
- Disease by body system or component
- Human disease
Narrower conditions (803)
- 16q24.1 microdeletion syndrome
- Acinar dysplasia
- Acinar dysplasia caused by mutation in FGF10
- Acinar dysplasia caused by mutation in FGFR2
- Acinar dysplasia caused by mutation in TBX4
- Acinar lung adenocarcinoma
- Acquired laryngomalacia
- Acropectorovertebral dysplasia
- Acute asthma
- Acute bronchiolitis
- Acute chest syndrome
- Acute epiglottitis
- Acute ethmoiditis
- Acute fibrinous and organizing pneumonia
- Acute frontal sinusitis
- Acute interstitial pneumonia
- Acute laryngitis
- Acute laryngopharyngitis
- Acute lung injury
- Acute maxillary sinusitis
Trials (1,840)
- "ADEN Platform: Pilot Clinical Validation for Chronic Disease Risk Stratification in Colombia"
- "Inspiratory Muscle Training in Older Women"
- "The Effect of Inhaled Nitroglycerin for COPD Patients
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- 12 Steps of a Modified Handwashing Program on Health Outcomes and School Absenteeism
- 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
- 2014TP001 - Assessing the Biology of the Injured Lung - Version 1
- 23andMe IPF Research Study
- 24-Hour NAVA Ventilation in Acute Respiratory Failure
- 50% Effective Concentration of Sevoflurane for Immobility
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- A Behavioral Circuit Breathing Training Intervention on Smoking Cessation and Respiratory Function Among Youth Who Use E-cigarettes
- A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
- A Clinical Study of TRUVIEW ART™(Advanced Reconstruction Tech)to Improve Image Quality on Chest Radiograph
- A Clinical Study to Map the HLA Genomic Region in the Greek Population
- A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
Approved drugs (16)
- Almitrine
- Almitrine mesylate
- Colfosceril palmitate
- Dimefline hydrochloride
- Doxapram
- Ethamivan
- Garenoxacin mesylate
- Ibuproxam
- Ivacaftor
- Lascufloxacin
- Levofloxacin
- Nikethamide
- Nitric oxide
- Palivizumab
- Piperacillin sodium
- Pirfenidone
Drugs in development (37)
- Acetylcysteine Phase 3
- Aderamastat Phase 1
- Alectinib Phase 2
- AM-461 Phase 1
- Ambroxol Phase 3
- Aspirin Phase 2
- BCG vaccine Phase 3
- Bemegride Phase 2
- Budesonide Phase 3
- Ciclesonide Phase 3
- Dimefline Phase 2
- Dupilumab Phase 2
- Glycine Phase 2
- GSK-1995057 Phase 1
- Human immunoglobulin G Phase 2
- Hymecromone Phase 1
- Idrevloride Phase 1
- Ifetroban Phase 2
- Linagliptin Phase 3
- Mepixanox Phase 2
Other linked drugs (9)
- Dexmedetomidine
- Fluticasone
- Midazolam
- Midazolam maleate
- Propofol
- Remifentanil
- Remimazolam
- Salmeterol
- Sufentanil